Anxiety disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anxiety disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to Current Treatment https://clinicaltrials.eu/trial/study-on-troriluzole-for-patients-with-obsessive-compulsive-disorder-not-responding-to-current-treatment/ Wed, 29 Apr 2026 15:01:18 +0000 https://clinicaltrials.eu/trial/study-on-troriluzole-for-patients-with-obsessive-compulsive-disorder-not-responding-to-current-treatment/ This clinical trial is focused on studying Obsessive Compulsive Disorder (OCD), a condition characterized by unwanted and repeated thoughts, feelings, ideas, or behaviors that make a person feel driven to do something. The study is investigating a treatment called Troriluzole, which is being tested as an additional therapy for individuals with OCD who have not responded adequately to their current treatment. Troriluzole is taken in the form of a capsule and is being compared to a placebo to evaluate its effectiveness.

The purpose of the study is to assess how well Troriluzole works in improving OCD symptoms. Participants will continue their current OCD medication while taking either Troriluzole or a placebo. The study will monitor changes in the severity of OCD symptoms over time, using a standard measurement tool known as the Y-BOCS score, which helps to quantify the severity of obsessive-compulsive symptoms.

Throughout the study, participants will be asked to take the medication orally for a period of up to 10 weeks. The study aims to provide insights into whether Troriluzole can be an effective addition to existing OCD treatments, potentially offering a new option for those who have not found relief with their current medication regimen.

]]> Study on Personalized Dosing of Sertraline, Aripiprazole, and Risperidone for Patients with Mood, Anxiety, or Psychotic Disorders https://clinicaltrials.eu/trial/study-on-personalized-dosing-of-sertraline-aripiprazole-and-risperidone-for-patients-with-mood-anxiety-or-psychotic-disorders/ Wed, 29 Apr 2026 14:58:04 +0000 https://clinicaltrials.eu/trial/study-on-personalized-dosing-of-sertraline-aripiprazole-and-risperidone-for-patients-with-mood-anxiety-or-psychotic-disorders/ This clinical trial is focused on studying the effects of certain medications on individuals with various mental health conditions. The diseases being studied include major depressive disorder, bipolar disorder (currently in a depressive episode), anxiety disorders such as panic disorder and generalized anxiety disorder, and psychotic disorders like schizophrenia and schizoaffective disorder. The medications involved in this study are sertraline, escitalopram, aripiprazole, and risperidone. These medications are commonly used to treat mood, anxiety, and psychotic disorders.

The purpose of the study is to compare how well patients respond to medication doses that are personalized based on their genetic makeup, known as pharmacogenetics, versus the usual dosing methods. Participants will be randomly assigned to receive either the personalized dosing or the usual dosing, which may include a placebo. The study will last for 24 weeks, during which participants will take the medication orally in the form of tablets. Throughout the study, participants’ recovery, well-being, and quality of life will be monitored, along with any side effects they may experience.

Pharmacogenetics is a field of medicine that looks at how a person’s genes can affect their response to drugs. By understanding these genetic differences, doctors can tailor treatments to each individual, potentially improving the effectiveness of the medication and reducing side effects. This study aims to see if using pharmacogenetics can lead to better outcomes for patients with these mental health conditions.

]]> Long-Term Safety Study of Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to SSRI, Clomipramine, Venlafaxine, or Desvenlafaxine https://clinicaltrials.eu/trial/long-term-safety-study-of-troriluzole-for-patients-with-obsessive-compulsive-disorder-not-responding-to-ssri-clomipramine-venlafaxine-or-desvenlafaxine/ Wed, 29 Apr 2026 14:27:50 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-troriluzole-for-patients-with-obsessive-compulsive-disorder-not-responding-to-ssri-clomipramine-venlafaxine-or-desvenlafaxine/ This clinical trial is focused on studying the long-term safety of a treatment for Obsessive Compulsive Disorder (OCD). The treatment being tested is called Troriluzole, which is taken in the form of a capsule. Troriluzole is being used as an additional therapy for individuals with OCD who have not responded adequately to other medications such as SSRIs, clomipramine, venlafaxine, or desvenlafaxine.

The purpose of the study is to evaluate how safe and tolerable Troriluzole is when used over a long period. Participants in the study will take Troriluzole orally, and the study will monitor their health to ensure the treatment is safe. The study will last for a maximum of 144 weeks, during which participants will be regularly checked for any side effects or health changes.

Throughout the study, researchers will pay close attention to any adverse effects, including serious adverse events, any side effects that lead to stopping the treatment, and any significant changes in laboratory test results. This information will help determine if Troriluzole is a safe option for people with OCD who need additional treatment support.

]]> Study on Cannabidiol for Reducing Anxiety and PTSD Symptoms in Dutch Uniformed Personnel https://clinicaltrials.eu/trial/study-on-cannabidiol-for-reducing-anxiety-and-ptsd-symptoms-in-dutch-uniformed-personnel/ Wed, 29 Apr 2026 14:22:33 +0000 https://clinicaltrials.eu/trial/study-on-cannabidiol-for-reducing-anxiety-and-ptsd-symptoms-in-dutch-uniformed-personnel/ This clinical trial is focused on studying the effects of a treatment for individuals experiencing symptoms of anxiety disorders and Post-Traumatic Stress Disorder (PTSD). The treatment being tested is a substance called Cannabidiol (CBD), which is a chemical compound found in cannabis plants. In this study, CBD is administered in the form of capsules. The purpose of the study is to explore how a two-week course of CBD might help reduce anxiety symptoms before starting therapy for anxiety or PTSD.

The study involves participants who are Dutch uniformed personnel, such as police officers, firefighters, ambulance paramedics, military personnel, or veterans. Participants will take CBD capsules daily for two weeks. During this period, researchers will monitor changes in anxiety levels using a tool called Beck’s anxiety index. Additionally, the study will assess how CBD affects fear responses, stress regulation, and sleep quality. These assessments will involve questionnaires, physiological measurements, and a sleep watch to gather comprehensive data on the effects of CBD.

By examining these factors, the study aims to provide insights into whether CBD can be beneficial in managing anxiety symptoms and improving overall well-being before starting traditional therapy for anxiety or PTSD. The findings could potentially lead to new approaches in preparing individuals for therapy, enhancing their treatment outcomes.

]]>